Management of acute haemolysis (low dose primaquine)

A simplified process for field site staff to identify and manage any cases of suspected acute haemolysis in a clinical trial (such as trials involving low-dose primaquine)

 

 

Publication Version
2.0
Publication Code
CL09
Procedure Author
WWARN

Haemolysis in acute malaria is inevitable, the mean haemoglobin concentration usually falling within the first week, with recovery usually taking 28-42 days. Primaquine can cause additional haemolysis particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, therefore clinical staff need to be vigilant for the signs and symptoms of haemolysis and the risk of trial subjects becoming anaemic. This procedure describes a simplified process for field site staff to identify and manage any cases of suspected acute haemolysis in a clinical trial (such as trials involving low-dose primaquine).